LYEL · Lyell Immunopharma reported Q3 2026 net loss of $45.5M, wider than the…

Lyell Immunopharma reported Q3 2026 net loss of $45.5M, wider than the $38.8M loss in Q3 2025, driven by increased R&D spending on clinical trials. The company announced updated ronde-cel data showing a 91% overall response rate and 77% complete response rate in the 3L+ PiNACLE trial, and completed an $80M private placement to extend cash runway into 2028.

• Q3 2026 net loss of $45.5M vs $38.8M in Q3 2025
• Revenue of $3K vs $15K in Q3 2025
• R&D expenses increased to $40.9M from $28.2M YoY
• Cash, equivalents and marketable securities of $194.0M as of Sep 30, 2026